Current concepts of cardiovascular diseases in diabetes mellitus (Q28196278)

International Journal of Cardiology

Europe PubMed Central

title

Current concepts of cardiovascular diseases in diabetes mellitus (English)

0 references

main subject

cardiovascular disease

1 reference

Jaffar Ali Raza

1

0 references

Assad Movahed

series ordinal

2

0 references

language of work or name

English

0 references

publication date

June 2003

0 references

published in

0 references

volume

89

0 references

issue

2-3

0 references

page(s)

123-34

0 references

cites work

Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Diabetes and decline in heart disease mortality in US adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Myocardial infarction in Mexican-Americans and non-Hispanic whites. The San Antonio Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Glucose intolrrance and diabetic complications among Japanese-American women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Diabetes mellitus and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Metabolic syndrome and ischemic heart disease in elderly men and women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Characterization of the insulin resistance of aging

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Relationships of generalized and regional adiposity to insulin sensitivity in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Endothelial dysfunction in the coronary microcirculation: a new clinical entity or an experimental finding?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Mononuclear cell adherence to cultured endothelium is enhanced by hypertension and insulin resistance in healthy nondiabetic volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Circulating endothelin-1 levels in obese patients with the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Insulin causes endothelial dysfunction in humans: sites and mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Insulin stimulates both endothelin and nitric oxide activity in the human forearm.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Association between C-reactive protein and features of the metabolic syndrome: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Elevated C-reactive protein levels in overweight and obese adults

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Advanced glycation end-products and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Oxidative stress and lipids in diabetes: a role in endothelium vasodilator dysfunction?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

The role of platelets in diabetes-related vascular complications

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Increased platelet thromboxane receptor sensitivity in diabetic patients with proliferative retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Decreased Sensitivity of Platelets to Prostacyclin in Patients with Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Nitric oxide-dependent soluble guanylate cyclase activity is decreased in platelets from male NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Evidence for abnormal platelet glycoprotein expression in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Low levels of intraplatelet cGMP in IDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Increase in the cytosolic concentration of calcium in platelets of diabetics type II.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Platelet abnormalities in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Vascular prostacyclin may be reduced in diabetes in man

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Inactivation of endothelial derived relaxing factor by oxidized lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Platelet hyperaggregation and increased plasma level of von Willebrand factor in diabetics with retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

All ras proteins are polyisoprenylated but only some are palmitoylated

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Deranged platelet calcium homeostasis in poorly controlled IDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

The increased percentage of megathrombocytes in various clinical disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Diabetes mellitus and cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Greater effect of diabetes on LDL size in women than in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Insulin resistance as a major determinant of increased coronary heart disease risk in postmenopausal women with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Prevalence of asymptomatic myocardial ischaemia in diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Silent myocardial ischemia in patients with diabetes: who to screen

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Benefits of strict glucose and blood pressure control in type 2 diabetes: lessons from the UK Prospective Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Plasma homocyst(e)ine levels in men with premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Homocysteine and cardiovascular disease in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Diabetes, hypertension, and cardiovascular disease: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

The Outcome of STOP-Hypertension-2 in Relation to the 1999 WHO/ISH Hypertension Guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Relation of lipoprotein(a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients > or =65 years of age (The Italian Longitudinal Study on Aging).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Aspirin as an antiplatelet drug

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Clinical pharmacology of platelet cyclooxygenase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Aspirin therapy in diabetes. American Diabetes Association

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900510-7

7 January 2021

10.1016/S0167-5273(02)00510-7

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

12767534

1 reference

Consolidated OpenCitations Corpus – April 2017